Aytu BioPharma, Inc. (AYTU)
- Previous Close
2.7800 - Open
2.9000 - Bid --
- Ask --
- Day's Range
2.8800 - 2.9150 - 52 Week Range
1.3800 - 3.5000 - Volume
6,144 - Avg. Volume
20,676 - Market Cap (intraday)
16.17M - Beta (5Y Monthly) -1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-4.0100 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.
aytubio.com150
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: AYTU
Performance Overview: AYTU
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AYTU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AYTU
Valuation Measures
Market Cap
16.17M
Enterprise Value
12.68M
Trailing P/E
--
Forward P/E
5.81
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.14
Price/Book (mrq)
0.49
Enterprise Value/Revenue
0.13
Enterprise Value/EBITDA
4.10
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.27%
Return on Assets (ttm)
-2.58%
Return on Equity (ttm)
-45.75%
Revenue (ttm)
98.5M
Net Income Avi to Common (ttm)
-18M
Diluted EPS (ttm)
-4.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
19.53M
Total Debt/Equity (mrq)
55.57%
Levered Free Cash Flow (ttm)
11.39M